Clinical Trials Browser

Phase 1/2 × OTHER × Dasatinib × Clear all

NCT05036226 2026-05-13

COAST

Phase 1/2 Recruiting

GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

NCT05192889 2025-09-22

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Phase 1/2 Active not recruiting

35 enrolled 12 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05751044 2025-09-16

HEM-iSMART B

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02954523 2024-07-05

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase 1/2 Terminated

10 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00550615 2023-09-26

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Completed

38 enrolled 9 charts

Lymphoma, Non-Hodgkin

NCT00788125 2023-07-14

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Phase 1/2 Terminated

7 enrolled 9 charts

CNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Familial ependymoma, Ovarian Germ Cell Cancer, Testicular Germ Cell Tumor, Astrocytoma, Burkitt Lymphoma, Carcinoma, Renal Cell, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Liver Neoplasms, Lymphoma, Medulloblastoma, Wilms Tumor, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Spinal Cord Neoplasms, Teratoma, Testicular Neoplasms, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Nephroma, Mesoblastic, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT01306942 2023-03-30

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Phase 1/2 Completed

37 enrolled 30 charts

Breast Neoplasms

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

Lymphoma, T-Cell, Peripheral

NCT04006847 2022-07-01

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Phase 1/2 Terminated

1 enrolled 5 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT01876953 2022-03-31

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

Phase 1/2 Terminated

20 enrolled 9 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT00566618 2022-02-25

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Phase 1/2 Completed

31 enrolled 8 charts

Breast Neoplasms

NCT01498445 2020-10-22

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Phase 1/2 Terminated

32 enrolled 16 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00869401 2020-02-13

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1/2 Completed

217 enrolled 12 charts

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00949988 2019-08-14

BMS-CA180105

Phase 1/2 Terminated

3 enrolled 3 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00820170 2019-08-13

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Phase 1/2 Completed

55 enrolled 19 charts

Breast Neoplasms, Neoplasms

NCT00829647 2019-04-11

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00826449 2016-06-28

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

53 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00850382 2016-03-01

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast Neoplasms

NCT00924352 2014-10-13

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Phase 1/2 Completed

56 enrolled 14 charts

Breast Neoplasms

NCT00597038 2013-12-16

A Phase I/II Study of Dasatinib and Dacarbazine

Phase 1/2 Completed

50 enrolled 11 charts

Melanoma